drugset / Trial / NCT06063317
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab and with or without hydroxyurea in adults with advanced or metastatic solid tumors.
Timeline
- Start
- 2023-10-02
- Primary completion
- 2026-02-02
- Completion
- 2026-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | — | Other |
| Subject | CF33-CD19 | Unknown | — | Other |
| Subject | Hydroxyurea | Other / unclassified | — | Oral |